<DOC>
	<DOCNO>NCT02370706</DOCNO>
	<brief_summary>This phase Ib study primary purpose estimate MTD and/or RDE triple combination PIM447 , formerly LGH447 , plus ruxolitinib LEE011 well doublets , PIM447 plus ruxolitinib , LEE011 plus ruxolitinib , patient myelofibrosis ( MF ) . Each regimen assess safety , tolerability , pharmacokinetics ( PK ) pharmacodynamic effect , preliminary anti-myelofibrosis activity , include change spleen volume , JAK2V617F allele burden , hematologic response .</brief_summary>
	<brief_title>Study Safety PIM447 Combination With Ruxolitinib ( INC424 ) LEE011 Patients With Myelofibrosis</brief_title>
	<detailed_description />
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<criteria>Eastern Cooperative Oncology Group ( ECOG ) performance status 0 2 . Patient must diagnose JAK2V617Fpositive primary secondary MF . Doseescalation Expansion part : Patients &lt; 35 % reduction spleen volume MRI/CT &lt; 50 % reduction spleen size physical exam , without correspond symptomatic improvement , least 6 month treatment single agent ruxolitinib optimal dose level line label recommendation . Expansion part : Ruxolitinibnaive patient patient previously treat single agent ruxolitinib relapse and/or refractory . Patients must splenomegaly measure least 5 cm MRI baseline . Have adequate bone marrow function : Platelets ≥ 100,000 mm3 without assistance growth factor platelet transfusion Absolute Neutrophil Count ( ANC ) ≥ 1500/mm3 without growth factor support within 7 day prior test Hemoglobin ≥ 9 g/dL . Systemic antineoplastic therapy ( include unconjugated therapeutic antibody , toxin immunoconjugates , alphainterferon ) experimental therapy within 14 day 5 halflives , whichever short , first dose study treatment Major surgery within 2 week first dose either study drug . Patients splenic irradiation within 2 week prior Screening prior splenectomy . Patients AML , MDS , peripheral blast ≥ 10 % Prior autologous allogeneic stem cell transplant time . Patients currently receive treatment prohibit medication discontinue least one week prior start treatment : substrate CYP3A4/5 , CYP2B6 CYP2D6 narrow therapeutic window strong inhibitor CYP3A4/5 CYP2D6 potent inducer CYP3A4/5 CYP2D6 Serum total bilirubin &gt; 1.5 x upper limit normal ( ULN ) except patient Gilbert 's syndrome exclude total bilirubin &gt; 3.0 x ULN direct bilirubin &gt; 1.5 x ULN , aspartate aminotransferase ( AST ) ( serum glutamic oxaloacetic transaminase [ SGOT ] ) ALT ( SGPT ) &gt; 3 x ULN , except patient MF involvement liver exclude AST ALT &gt; 5 x ULN . Serum creatinine &gt; 1.5 x ULN calculate creatinine clearance &lt; 60 ml/min accord CockcroftGault equation Electrolyte abnormality CTCAE grade ≥ 2 ( e.g . serum potassium , magnesium calcium ) unless replete screening deem clinically significant Investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>PIM447</keyword>
	<keyword>LGH447</keyword>
	<keyword>PIM inhibitor</keyword>
	<keyword>LEE011</keyword>
	<keyword>CDK 4/6 inhibitor</keyword>
	<keyword>ruxolitinib</keyword>
	<keyword>INC424</keyword>
	<keyword>Jakavi®</keyword>
	<keyword>Jakafi®</keyword>
	<keyword>INCB18424</keyword>
	<keyword>JAK inhibitor</keyword>
	<keyword>myelofibrosis</keyword>
	<keyword>PMF</keyword>
	<keyword>PPV-MF</keyword>
	<keyword>PET-MF</keyword>
</DOC>